post-progression analysis of mariposa-2: amivantamab chemo in egfr nsclc
Published 6 months ago • 276 plays • Length 3:21Download video MP4
Download video MP3
Similar videos
-
3:16
mariposa-2: second interim os of amivantamab and chemotherapy in egfr-m nsclc
-
2:04
mariposa-2: amivantamab chemo (± lazertinib) vs chemo in egfr-mutated nsclc post-osimertinib
-
6:15
mariposa: longer-term follow-up of amivantamab & lazertinib in egfr-m nsclc
-
4:17
highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2
-
3:17
phase iii mariposa: amivantamab lazertinib vs osimertinib in egfr-mutated nsclc
-
0:56
second line treatment in activating egfr non-small cell lung cancer, mariposa - 2 | onc brothers
-
18:29
esmo 2023 lung cancer - chapter 2 highlights – papillon, mariposa, mariposa-2, libretto-431
-
2:08
mariposa: mechanisms of resistance to 1l amivantamab lazertinib in pts with egfr-m nsclc
-
0:59
managing amivantamab infusion reaction #2023 #oncology #lungcancer
-
1:34
pros in papillon trial: amivantamab chemo for egfr exon 20 nsclc
-
1:27
mariposa: follow-up of lazertinib with amivantamab or osimertinib in egfr-m nsclc
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
3:50
amivantamab plus lazertinib is a new standard for egfr-mutant nsclc
-
0:56
the clinical impact of amivantamab and chemotherapy in egfrm nsclc
-
2:07
papillon: amivantamab plus chemotherapy in nsclc with egfr exon 20 insertions
-
0:55
mariposa update - amivantamab lazertinib in 1l egfr mutated metastatic nsclc.
-
1:27
papillon phase iii primary results: amivantamab chemo vs chemo in egfr exon 20 nsclc
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc
-
0:58
first line treatment options for activating egfr non-small cell lung cancer | dr. alexander spira